BioStock: CombiGene one step closer to clinical trials
In recent weeks, CombiGene has lined up several milestones on the way to the goal of initiating clinical trials in patients with drug-resistant focal epilepsy. The latest milestone was reached on September 28 when the company announced that it, together with the Spanish manufacturer Viralgen, will begin large-scale production of the primary drug candidate CG01 for future safety and biodistribution studies. CEO Jan Nilsson gave a brief comment to BioStock.
Read the full interview with Jan Nilsson, CEO of CombiGene, at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se